Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

As DaVita marks a major milestone, its top executive reveals where the Dever-beased business and its 3,000 downtown employees ...

TD Cowen analyst Gary Taylor raised the firm’s price target on DaVita (DVA) to $165 from $150 and keeps a Hold rating on the shares. The firm ...

Cauliflower brings the crunch, paired with plenty of vitamins C, B6, B9 and K, along with fiber. It also contains compounds your body can use to neutralize certain toxins, a big help when your kidneys ...

DaVita, a leading provider of kidney care services, today announced the success of its third annual Move It With Purpose (MIWP) event with more than 8,300 participants, including DaVita teammates, ...

DaVita shares plunged 11% on February 14 after issuing a weaker-than-expected 2025 earnings outlook. The decline was further ...

Q4 2024 Earnings Call Transcript February 13, 2025 DaVita Inc. beats earnings expectations. Reported EPS is $2.24, ...

Warren Buffett sold a big stake in a healthcare provider - causing the share price to sink 11 per cent. The 94-year-old ...

Shares of DaVita Inc ( DVA -11.09%) are trading lower on Friday. The company's stock lost 11.1% as of market close but lost ...

Shares of healthcare company DaVita (DVA) are down 11% on reports that Warren Buffett has reduced his holding of the ...

DaVita Inc.'s stock was tumbling 13.5% Friday to lead S&P 500 decliners, after Warren Buffett's Berkshire Hathaway Inc. pared its stake in the provider of kidney dialysis.

Major U.S. equity indexes were mixed and little changed at midday Friday after a report showed a larger-than-expected decline in U.S. retail sales.